HUMAN RECOMBINANT ADENOSINE A2A RECEPTOR
MULTISCREEN™ STABLE CELL LINES
1 vial (2 x 106) frozen cells
Sigma Freezing Medium (C-6164)
Full-length Human ADORA2A cDNA (GenBank Accession Number NM_000675.4) with FLAG-tag sequence at the N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DME/F12, 10% FBS, 10 µg/mL puromycin
Stable in culture for minimum of two months
Background: Adenosine regulates the function of the innate and adaptive immune systems through targeting virtually every cell type that is involved in orchestrating an immune/inflammatory response. Of the four adenosine receptors (A1, A2A, A2B, A3), A2A receptor is the primary anti-inflammatory effectors of extracellular adenosine. A2A receptor predominant expresses in monocytes/macrophages, dendritic cells, mast cells, neutrophils, endothelial cells, eosinophils, epithelial cells, as well as lymphocytes, NK cells, and NKT cells. Its activation inhibits early and late events occurring during an immune response. A2A receptor also participates in tissue remodeling and reparation. A2A receptor has been shown to impact the course of a wide spectrum of ischemic, autoimmune, infectious, and allergic diseases, and has regulatory roles in immune/inflammatory diseases of various organs, including heart, lung, gut, liver, kidney, joints, and brain. Recently, A2A receptor has become a particularly attractive target to manage psychiatric disorders.
Application: Functional assays
Figure 1. Dose-dependent stimulation of intracellular cAMP level upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01). Figure 2. Dose-dependent stimulation of calcium flux upon treatment with ligand, measured with MultiscreenTM Calcium 1.0 No Wash Assay Kit (Multispan MSCA01).
Haskó and Pacher (2008) A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 83:447-455.
Cunha et al. (2008) Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 14:1512-1524.